Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTX-205
- Development stage
- Preclinical
- Lead developer
- Providence Therapeutics
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
PTX-205 is an mRNA-based vaccine candidate being developed by Providence Therapeutics for the prevention of infection caused by highly pathogenic influenza viruses. The vaccine utilizes messenger RNA technology to deliver genetic sequences encoding specific influenza virus antigens into host cells. Once translated, these antigens trigger a robust and targeted immune response, including the production of neutralizing antibodies and the activation of T cells, to establish protective antiviral immunity. PTX-205 is currently in the pre-IND (Investigational New Drug) stage of development, representing a key component of Providence's infectious disease portfolio focused on high-risk viral pathogens.
Beyond the preview
Go deeper on PTX-205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTX-205.